The Possible Efficacy and Safety of L-carnitine and Biotin as Adjunctive Therapies in Children With Moderate Persistent Asthma
NCT ID: NCT05632549
Last Updated: 2022-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
66 participants
INTERVENTIONAL
2022-08-08
2024-08-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
Placebo
Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
L-carnitine
Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
L-Carnitine 500Mg Oral Tablet
Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
Biotin
Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
Biotin Capsules
Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
L-Carnitine 500Mg Oral Tablet
Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
Biotin Capsules
Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age range of 8-\< 18 years old
* Both sex
Exclusion Criteria
* Children with immunodeficiency.
* Children with thyroid disorder.
* Children with recent infection (especially pneumonia), surgery, anesthesia.
* Children having clinical evidence of any heart renal and hepatic diseases.
* Children having cystic fibrosis or congenital respiratory disease.
* Children having chronic diarrhea and mal-absorption.
* Children having clinical evidence of malnutrition.
* Children on medications that could interfere with L-carnitine level including antibiotics use. (particularly ampicillins) and anti- convulsing particularly valoproic acid.
8 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed osama khedr
Clinical pharmacist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University Hospital
Tanta, Gharbia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35652/8/22
Identifier Type: -
Identifier Source: org_study_id